| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Naxitamab
CAS:1879925-92-4
Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Naxitamab (anti-GD2)
CAS:1879925-92-4
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10706
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Naxitamab
CAS:1879925-92-4
Purity:95% Package:1mg;1g;100g
|
Naxitamab manufacturers
- Naxitamab
-
- $189.00
-
2026-08-18
- CAS:1879925-92-4
- Purity: 100% (SEC-HPLC)
- Supply Ability: 10g
|
| | Naxitamab Basic information |
| Product Name: | Naxitamab | | Synonyms: | Naxitamab;Research Grade Naxitamab(DGK07803);Naxitamab (anti-GD2);Naxitamab-gqgk|||Humanized 3F8|||Hu3F8;Research Grade Naxitamab | | CAS: | 1879925-92-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Naxitamab Structure]() |
| | Naxitamab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Naxitamab Usage And Synthesis |
| Uses | Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1]. | | in vivo | Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts[1]. | Animal Model: | Female athymic nude mice with LAN-1 xenografts[1] | | Dosage: | 100 mg/kg | | Administration: | Intravenous injection; twice a week, for 4 weeks | | Result: | Inhibited tumor growth and prolonged the survival time. |
| | References | [1] Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1(4):477-486. DOI:10.4161/onci.19864
[2] Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-296. DOI:10.1007/s40265-021-01467-4 |
| | Naxitamab Preparation Products And Raw materials |
|